Fair Trade Regulator Clears Wipro GE Healthcare-GE India Technology Deal
New Delhi: The Competition Commission of India (CCI) has approved medical equipment firm Wipro GE Healthcare's proposed deal to acquire GE group's bio-technology and life sciences-related assets.
According to the fair trade regulator, "the proposed combination is not likely to have appreciable adverse effect on competition in India".
Under the deal, Wipro GE would acquire assets of GE India Technology Centre - part of US-headquartered conglomerate General Electric group - used in the research areas of bio-technology and life sciences.
CCI observed that while Wipro GE is engaged in manufacturing and distribution of various medical equipment and solutions including life sciences equipment and devices, GE India Technology is into multi-disciplinary research and development in various technologies such as bio-technology.
"Accordingly, it is observed that there is no horizontal overlap between the businesses of Wipro GE and GE India Technology Centre Ltd," the regulator said in an order released on Friday.Â
Further, CCI noted that "the proposed combination would facilitate vertical integration of the businesses of Wipro GE as it would enable Wipro GE to sell equipment as well as provide related research and other support services in biotech and life-sciences areas".
"It is also observed that GE India Technology Centre renders 100 per cent of its services to the affiliates of GE group across the world, including India," CCI said.
"Therefore, this vertical integration is unlikely to result in any appreciable adverse effect on competition," the
fair trade regulator added.
The 'asset purchase agreement' was entered between the two companies on July 7, 2014, following which they had approached the competition watchdog for approval in the same month.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
